Keros Therapeutics, Inc. $KROS Shares Sold by Madison Avenue Partners LP

Madison Avenue Partners LP lessened its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 69.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 823,707 shares of the company’s stock after selling 1,884,511 shares during the period. Keros Therapeutics makes up approximately 0.7% of Madison Avenue Partners LP’s investment portfolio, making the stock its 19th largest position. Madison Avenue Partners LP’s holdings in Keros Therapeutics were worth $16,771,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in KROS. Western Standard LLC raised its stake in shares of Keros Therapeutics by 42.7% during the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after buying an additional 654,989 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Keros Therapeutics by 282.5% during the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after buying an additional 436,986 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Keros Therapeutics during the 2nd quarter worth $4,251,000. Caption Management LLC raised its stake in shares of Keros Therapeutics by 114.1% during the 2nd quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after buying an additional 291,997 shares during the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in shares of Keros Therapeutics by 683.7% during the 3rd quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock worth $4,795,000 after buying an additional 264,445 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Alpna Seth sold 2,625 shares of Keros Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the transaction, the director directly owned 9,767 shares of the company’s stock, valued at $104,702.24. The trade was a 21.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the transaction, the director directly owned 9,767 shares in the company, valued at $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,425 shares of company stock worth $89,995 in the last 90 days. 20.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

KROS has been the subject of several research reports. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Wells Fargo & Company cut their price target on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Finally, Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.40.

Keros Therapeutics Trading Up 3.8%

Keros Therapeutics stock opened at $10.41 on Thursday. The stock has a market cap of $206.01 million, a PE ratio of -3.46 and a beta of 0.94. The stock has a 50-day moving average price of $11.13 and a 200 day moving average price of $14.75. Keros Therapeutics, Inc. has a 52 week low of $9.69 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The business had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. On average, equities analysts predict that Keros Therapeutics, Inc. will post -5.19 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.